Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,483 total articles
AeroVironment is squarely in the crosshairs of rising defense spending and demand for counter-drone technology. With a $8.14B market cap, improving program wins (including a shipboard laser demo) and favorable technicals around oversold territory, AVAV looks like a tactical long from $165 with a $305 target and a $150 stop. The idea carries materia…
Vipshop (VIPS) beat expectations in its latest quarter, and while urban Chinese consumption is uncertain, the stock trades at a low PE (7.2) with a $0.60 annual distribution and a near-term technical setup that favors buyers. This trade plan targets a material re-rating toward historical mid-teens multiples while limiting downside at the 52-week lo…
Compass is a technology-enabled real estate platform that looks inexpensive on EV/sales and has tangible merger synergies after the Anywhere combination. This trade idea lays out a specific entry at $8.50, a protective stop at $6.50, and two pragmatic upside targets at $12.00 (mid-term) and $16.00 (long-term), with a plan tied to a housing-market r…
Roblox's recent reset after mandatory age-verification costs has materially compressed the stock. That pullback creates an actionable swing trade: buy near $46 to capture upside from 18+ cohort monetization and improving technical momentum, with a clear stop under the recent low. The idea leans on elevated ARPU potential, solid free cash flow, cons…
American Coastal Insurance (ACIC) trades at a single‑digit P/E with EV/EBITDA near 3x, a recent underwriting leadership move, and a special dividend that underscores cash generation. Technicals are neutral-to-firm and downside is definable. We upgrade to a buy and lay out an actionable entry, stop and targets for a mid‑term swing trade (45 trading …
Farmers & Merchants Bancorp (FMCB) checks a lot of boxes for conservative income-plus-growth investors: record 2025 net income, industry-leading dividend streaks, and an enlarged $57.6M repurchase authorization. At $1349.99 the shares trade at roughly a 10x P/E on recent EPS and offer a modest ~1.6% yield. Technicals show strength but near-term mom…
Microsoft's core franchises continue to generate cash and margin expansion potential while valuation sits at a reasonable multiple for quality growth. This trade idea lays out an actionable long with entry, stop and target, a catalyst list, and balanced risk discussion.
DexCom's shares are trading near $72 after a solid Q1 print, margin guidance and a fresh $1 billion buyback. The business is cash-generative, profitable and still growing: revenue was $1.2B in the most recent quarter (up ~15% YoY), adjusted gross-profit margin targets sit at 67-69% and cash on the balance sheet is roughly $2.4B. At ~29-30x reported…
Vermilion Energy (VET) has the makings of a classic re-rating setup: improving cash returns to investors, asset sales that reduce leverage and a market cap below $2 billion that still trades well under what a sustainably higher multiple could justify. This trade idea lays out a clear entry at $12.30, a stop at $10.50 and a target of $15.00 over a l…
Nvidia's blowout quarter (Q1 FY2027) and aggressive capital return make new all-time highs very likely. This trade idea lays out a specific long entry at $220.12, a protective stop at $195.00, and a primary target of $320.00, with timeline and risk management across short, mid and long horizons.
Ironwood offers an asymmetric risk-reward right now. The shares trade near $3.85 with a market cap ~ $640M, EV/EBITDA under 5 and free cash flow of $112M. Recent guidance from management for materially higher LINZESS U.S. net sales and a paradoxical list-price move that improved net pricing reset the narrative in January 2026. Meanwhile short inter…
Nvidia reported $81.6B in revenue and $75.2B in Data Center sales, added an $80B buyback authorization, and still traded off after the print. The numbers point to durable, hyperscaler-led demand for AI compute. This trade idea lays out a long entry at $220.12, a $260 target and a $200 stop, with a 180 trading-day horizon and medium risk sizing.
Applied Digital just announced a 15-year, $7.5B lease for 300 MW at Polaris Forge 3, taking its disclosed contracted lease revenue to roughly $31B and total contracted capacity to ~1GW. The market is rewarding scale; this trade idea buys a measured pullback to ride continued hyperscaler demand while respecting execution and valuation risks.
AeroVironment (AVAV) is trading well below its prior highs despite clear product demonstrations and pipeline wins. With a market cap near $8.1B, improving contract flow, and visible technology momentum in directed energy and AI-enabled perception, the risk/reward into the next earnings release looks favorable. This trade plan outlines a mid-term lo…
CRISPR Therapeutics ($CRSP) is priced like a growth story with a $4.8B market cap while the market waits on several clinical readouts and label expansion that could re-rate the shares. This trade idea lays out a long bias with an entry at $49.90, a stop at $40.00 and a $85.00 target tied to positive Phase 2/Phase 1 data and commercial progress.
Rolls-Royce (RYCEY) looks like a constructive long setup: core aerospace and aftermarket profitability remains solid, the company sits squarely in the early winners' circle for small modular reactors (SMRs) after fresh UK funding, and the stock has pulled back on sentiment rather than fundamentals. This trade targets a recovery toward the 52-week h…
MPLX pairs a near-8% distribution with stable, fee-based cash flows and multiple growth projects coming online. At $55.65 the unit is trading on reasonable multiples (P/E ~12, EV/EBITDA 14.2) while returning >$5.8B in distributable cash flow and $3.9B in free cash flow. This trade favors a mid-term, income-with-upside approach: enter at $55.65, sto…
Meta is pivoting capital and talent toward AI at scale. The company trades at a reasonable multiple for a cash-generative platform and offers optionality from Reality Labs and next-gen AI products. This trade sets a defined entry, stop and target for a long-term (180 trading days) exposure to that upside while acknowledging capex risk and execution…
Meta is spending aggressively on AI infrastructure and Reality Labs hardware, which has pressured free cash flow and drew criticism. But the same investments are expanding gross margins on ad inventory, locking in scale advantages for LLMs and AR products, and setting up a plausible multiple expansion from current levels. This trade idea buys Meta …
SSR Mining ($SSRM) has just executed the kinds of corporate actions that can force a multiple expansion: an announced $1.5B sale of an 80% stake in its Turkish Copler asset plus a board-approved repurchase of up to 10% of shares. With a clean balance sheet (cash ~$2.3B, debt-to-equity ~0.02), attractive EV/EBITDA (~6.4x) and a FCF run-rate that sup…
Dyne Therapeutics is a clinical-stage biotech with a differentiated antibody-oligonucleotide platform and a clear near-term regulatory catalyst: a planned biologics license application submission for z-rostudirsen in Q2 2026. The company carries a roughly $2.9B market cap, a strong cash runway and a net-cash cushion. We rate DYN Strong Buy as an ev…
lululemon (LULU) has been punished hard from its 52-week high, leaving the stock trading at single-digit forward multiples, healthy cash generation and virtually no net debt. Technicals suggest near-term oversold conditions and short interest remains meaningful. This trade idea lays out a long entry, stop and staged targets for a long-term (180 tra…
Ferrari (RACE) is a rare car company that behaves like a luxury consumer brand: limited production, pricing power, and industry-leading margins. At a market cap of ~$86.4B and a P/E of ~32.8, the stock is ~32% off its peak while fundamentals — 50.8% gross margin, 24.7% operating margin and a full order book through 2027 — still justify a premium. T…
Immunovant (IMVT) looks buyable after renewed conviction from Roivant and a constructive narrative around a difficult-to-treat rheumatoid arthritis program. The stock is trading near its 52-week high, momentum indicators are bullish, and the company has a meaningful cash cushion from a $550M financing. This trade plan is a mid-term momentum play wi…
Swatch Group ADR (SWGAY) is a beaten-but-not-broken luxury/watchplay that trades below book value, shows improving technicals, and carries an outsized short-interest footprint. If a retail-led rerate similar to recent momentum winners materializes, the stock can quickly reclaim its 52-week high and then some. This trade lays out a mid-term plan and…
